A multi-database pharmacovigilance study reveals distinctive immunosuppressive and opportunistic infection disproportionality signals with bevacizumab and temozolomide combination therapy in glioblastoma

BEV + TMZ combination therapy shows disproportionality signals for severe immunosuppression and opportunistic infections. These signal patterns, including time-to-onset distributions, may help prioritize clinical vigilance and hypothesis generation, but do not estimate incidence or establish causality and require prospective confirmation.